Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RisaKids: Risankizumab in Pediatric Crohn's Disease
NCT06298188Recruiting
- Sponsor
- Shaare Zedek Medical Center
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of risankizumab in Crohn's disease, sponsored by Shaare Zedek Medical Center. Primary endpoint: Complete remission at 54 weeks. Started Oct 2024; status: recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06298188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06298188.